Related Experiment Video

Updated: Mar 6, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.8K

Epidermal Growth Factor Receptor Inhibitor Rechallenge: A Worthy Option in the Crowded Refractory Advanced Colorectal

Suneel D Kamath1

  • 1Cleveland Clinic Cancer Center, Cleveland, OH.

JCO Oncology Practice
|March 4, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.5K

Related Experiment Videos

Last Updated: Mar 6, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.8K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K

Articles linked to this work by shared authors, journal, and citation graph.

Integrating Somatic and Germline Pharmacogenomics for Therapeutic Decisions in Precision Oncology.

JCO precision oncology·2026

PET-Assessed Metabolic Tumor Volume Across the Spectrum of Solid-Organ Malignancies: A Review of the Literature.

Biomedicines·2025

Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers.

JCO precision oncology·2024

Multi-omics machine learning to study host-microbiome interactions in early-onset colorectal cancer.

NPJ precision oncology·2024

Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma.

Cancers·2024

Disparities in National Cancer Institute and Nonprofit Organization Funding Disproportionately Affect Cancers With Higher Incidence Among Black Patients and Higher Mortality Rates.

JCO oncology practice·2024

Inflammatory Breast Cancer-The Evolution of Diagnosis and Modern Clinical Management.

JCO oncology practice·2026

Selection and Management of Patients With Resectable Gastric or Gastroesophageal Junction Cancer Receiving Perioperative FLOT: A Modified Delphi Consensus Approach.

JCO oncology practice·2026

Educating Pediatric Oncology Clinicians on Sexual Health Care for Adolescents and Young Adults With Cancer: Results From a Proof-of-Concept Study.

JCO oncology practice·2026

Ambient Artificial Intelligent Scribes in Oncology: Impact on Clinician Experience and Documentation Burden.

JCO oncology practice·2026

Mapping the Canadian Oncology Physician Workforce: A Review of Training, Distribution, and Systemic Pressures Across Oncology-Related Physician Specialties.

JCO oncology practice·2026

Reproducibility Status of Economic Evaluations of Cancer Drugs: An Assessment of 150 Cost-Effectiveness Models.

JCO oncology practice·2026

Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092).

Future oncology (London, England)·2026

Transarterial Computed Tomographic Angiography in Patients With Impaired Renal Function Undergoing Endovascular Aortic Repair.

Vascular and endovascular surgery·2026

8-Chloro-cyclic AMP mediates growth inhibition of breast cancer cells via regulation of Yin-Yang 1 and estrogen receptor α levels.

BMB reports·2026

Atorvastatin protects cardiomyocytes from doxorubicin toxicity by modulating YAP/TAZ signaling.

BMB reports·2026

Contrast-Associated Acute Kidney Injury in Oncology Patients During Active Chemotherapy: A Saudi Arabian Retrospective Study.

Medical science monitor : international medical journal of experimental and clinical research·2026

Dual-Targeting Nanomicelles Co-Loading Sorafenib and Artesunate Combats Hepatocellular Carcinoma via the Synergistically Enhanced Ferroptosis Strategy.

Advanced healthcare materials·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us